Summary
Twenty-three patients with malignant central nervous system tumors were treated with fludarabine phosphate (2-FAMP) on a 5 day bolus schedule. One brief partial response was observed in 20 malignant astrocytoma patients. 2FAMP as given in this protocol is inactive in previously treated patients with recurrent malignant astrocytomas.
Similar content being viewed by others
References
Hutton JJ, Von Hoff DD, Kuhn J, et al. Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5′-monophosphage (NSC 312887), a new purine antimetabolite. Cancer Res 44:4183–4186, 1984
Spriggs DR, Stopa E, Mayer RJ, Schorne W and Kufe DW. Fludarabine Phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res 46:5953–5958, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Taylor, S.A., Crowley, J., Vogel, F.S. et al. Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. Invest New Drugs 9, 195–197 (1991). https://doi.org/10.1007/BF00175089
Issue Date:
DOI: https://doi.org/10.1007/BF00175089